Electra Therapeutics, Inc. filed an 8-K report on September 21, 2026, disclosing the completion of its initial public offering (IPO) and the adoption of new corporate governance documents.
The company closed its IPO on September 21, 2026, selling an aggregate of 23,333,334 shares of common stock at a price to the public of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $350.0 million.
In connection with the IPO, the company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware. The board of directors and stockholders had previously approved the Restated Certificate to be effective upon the closing of the IPO. The company also adopted amended and restated bylaws effective as of September 21, 2026.
Electra Therapeutics is incorporated in Delaware and is listed on The Nasdaq Global Select Market under the ticker symbol ETRA. The company’s principal executive offices are located at 230 E Grand Avenue Suite S-100, South San Francisco, California 94080.
